Verastem, Inc.VSTMEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.
VSTM Q3 FY2025 Key Financial Metrics
Revenue
$11.2M
Gross Profit
N/A
Operating Profit
$-40.7M
Net Profit
$-98.5M
Gross Margin
N/A
Operating Margin
-362.2%
Net Margin
-876.3%
YoY Growth
N/A
EPS
$-1.35
Verastem, Inc. Q3 FY2025 Financial Summary
Verastem, Inc. reported revenue of $11.2M for Q3 FY2025, with a net profit of $-98.5M (down 311.1% YoY) (-876.3% margin).
Key Financial Metrics
| Total Revenue | $11.2M |
|---|---|
| Net Profit | $-98.5M |
| Gross Margin | N/A |
| Operating Margin | -362.2% |
| Report Period | Q3 FY2025 |
Verastem, Inc. Quarterly Revenue & Net Profit History
Verastem, Inc. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $11.2M | — | $-98.5M | -876.3% |
| Q2 FY2025 | $2.1M | -78.6% | $-25.9M | -1213.6% |
| Q3 FY2024 | $0 | — | $-24.0M | N/A |
| Q2 FY2024 | $10.0M | — | $-8.3M | -82.6% |
Income Statement
| Q2 2024 | Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Revenue | $10.0M | $0 | $2.1M | $11.2M |
| YoY Growth | N/A | N/A | -78.6% | N/A |
Balance Sheet
| Q2 2024 | Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Assets | $105.7M | $126.4M | $196.3M | $176.9M |
| Liabilities | $65.7M | $94.2M | $160.2M | $192.4M |
| Equity | $18.9M | $11.1M | $36.1M | $-15.5M |
Cash Flow
| Q2 2024 | Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Operating CF | $-27.6M | $-23.8M | $-32.7M | $-36.2M |